论文部分内容阅读
目的观察T2DM合并亚临床甲状腺功能减退(SCH)患者的临床特征。方法收集154例T2DM合并SCH患者(T2DM-SCH组)及183例单纯T2DM住院患者(T2DM组)资料及相关检查,并进行统计分析。结果 T2DM患者中,SCH患病率约18.1%。T2DM-SCH组eGFR较T2DM组降低,胱抑素C(Cys-C)较T2DM组升高(P<0.05)。校正年龄、病程、BMI及HbA_1c后,TSH与Cys-C呈正相关(r=0.291,P<0.01)。T2DM-SCH组年龄高、病程长、高血压及DR患病率高于T2DM组(P<0.05)。T2DM-SCH组血清游离甲状腺素(FT4)低于T2DM组,SUA、2hIns高于T2DM组(P<0.05)。结论 T2DM患者SCH患病率高。SCH患者糖脂代谢异常状态明显,SCH与糖尿病慢性肾脏疾病(CKD)、DR及高血压相关。T2DM患者筛查SCH有临床意义。
Objective To observe the clinical features of T2DM patients with subclinical hypothyroidism (SCH). Methods The data of 154 T2DM patients with T2DM (T2DM-SCH group) and 183 T2DM patients (T2DM group) were collected and analyzed statistically. Results The prevalence of SCH was about 18.1% in T2DM patients. The eGFR of T2DM-SCH group was lower than that of T2DM group, and the level of Cystatin C (Cys-C) was higher than that of T2DM group (P <0.05). TSH was positively correlated with Cys-C (r = 0.291, P <0.01) after adjusting for age, course of disease, BMI and HbA_1c. T2DM-SCH group had higher age, longer duration, higher prevalence of hypertension and DR than T2DM group (P <0.05). T2DM-SCH group serum free thyroxine (FT4) than T2DM group, SUA, 2hIns higher than T2DM group (P <0.05). Conclusion The prevalence of SCH in T2DM patients is high. SCH patients with abnormal glucose and lipid metabolism status, SCH and chronic kidney disease (CKD), DR and hypertension related. The screening of SCH in T2DM patients has clinical significance.